There is a report that 7.6% of patients worldwide suffer from osteoarthritis, and a study conducted in Korea indicates that 8.27% of Koreans are affected by this condition. Osteoarthritis not only causes pain but can also lead to swelling and joint stiffness. In Korea, nonsteroidal anti-inflammatory drugs (NSAIDs) and SYSADOA are often prescribed together for osteoarthritis patients. Recently, Duojoin®, a combination of these two types of medication, has become commercially available for treatment. The drug consists of celecoxib and PG201, both of which can reduce pain and improve function in osteoarthritis patients. Celecoxib is known to have fewer gastrointestinal side effects compared to other NSAIDs. Study suggests that Duojoin® can be more effective in reducing pain and improving function than celecoxib alone, making it a promising option for the treatment of osteoarthritis.
목차
Abstract 서론 본론 1. DuojoinⓇ의 성분 2. Celecoxib 3. SYSADOA in DuojoinⓇ 4. DuojoinⓇ의 임상 연구 결론 참고문헌
Jae Hun Kim [ 김재헌 | Department of Anesthesiology and Pain medicine, Konkuk University Medical Center, Seoul Korea/Department of Anesthesiology and Pain medicine, Konkuk University School of Medicine, Seoul, Korea ]
Corresponding Author
Sung Cheol Ko [ 고성철 | Department of Anesthesiology and Pain medicine, Konkuk University Medical Center, Seoul Korea ]